Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000319680 | SCV000332564 | likely benign | not specified | 2015-07-10 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001705406 | SCV000514165 | likely benign | not provided | 2021-04-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000545914 | SCV000650155 | benign | Epidermolysis bullosa simplex 5B, with muscular dystrophy; Epidermolysis bullosa simplex, Ogna type; Epidermolysis bullosa simplex 5C, with pyloric atresia; Autosomal recessive limb-girdle muscular dystrophy type 2Q; Epidermolysis bullosa simplex with nail dystrophy | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002518827 | SCV003680639 | uncertain significance | Inborn genetic diseases | 2021-08-23 | criteria provided, single submitter | clinical testing | The c.11692G>A (p.G3898S) alteration is located in exon 33 (coding exon 32) of the PLEC gene. This alteration results from a G to A substitution at nucleotide position 11692, causing the glycine (G) at amino acid position 3898 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV001705406 | SCV004184751 | likely benign | not provided | 2024-04-01 | criteria provided, single submitter | clinical testing | PLEC: BP4 |